*together with TheoTrade

Good day, 360!

Urgent webinar reminder – learn how Blake is BEATING the S&P 500 three times over… today at 1pm EST → lock in your seat here!

And while you’re at it, check out Jason Bond’s  Ultimate Options Trading Blueprint For Small Accounts. He’s on a HUGE winning streak. Trading is hard, but with Jason at your side, you can come into the arena prepared!

FOCUS LIST🔎

BLMZ – Up over 60% in the pre-market after being selected as the primary animation production contractor for an upcoming animation project

TVGN – Up over 40% in pre after highlighting promising trial data as CEO leads patient advocacy at Capitol Hill, pledging to leverage multi-billion dollar company assets to combat long COVID and spearhead a new wave of medical innovation

TPST – Up over 40% in pre after announcing agreement with Roche to support advancement of Amezalpat combination therapy into first-line Hepatocellular Carcinoma pivotal trial

HOTLIST🔥

BLMZ – Up over 60% in the pre-market after being selected as the primary animation production contractor for an upcoming animation project

BloomZ Inc. (BLMZ) is a Japanese anime production, audio production, and voice actor management company.

In the after-hours yesterday, the company announced that it was selected by the animation production committee of “Kakushite! Makina-san!,” an animation project scheduled to begin airing in 2025 as the primary animation production contractor.

In addition to becoming the primary animation production contractor for the Animation Production Committee, BloomZ has acquired the following rights:

Neighboring rights and ownership of the master recording of the opening music;

Overseas rights (which include theatrical distribution rights, television broadcasting rights, videogame rights, and all other rights to use the animation overseas); and

Commercialization rights and digital content rights (including the right to produce digital games).

The stock traded up over 60% in the pre-market in reaction to the news.

The $1.09 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $1.20 and then the pre-market high at $1.33. Beyond that, $1.70 and $2 come into play.

Below $1.09, targets to the downside are $1, $0.85 and then a gap fill at $0.7152.

TVGN – Up over 40% in pre after highlighting promising trial data as CEO leads patient advocacy at Capitol Hill, pledging to leverage multi-billion dollar company assets to combat long COVID and spearhead a new wave of medical innovation 

Tevogen Bio (TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers.

In the after-hours yesterday the company reissued its previously announced topline results from its Proof-of-Concept (POC) clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company’s first clinical product utilizing the internally developed ExacTcell™ technology, for the treatment of acute high-risk SARS-CoV-2 patients.

Highlights Include:

• The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. 

• Endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met.

• Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients.

• Treatment arm patients were infected by a variety of SARS-CoV-2 variants ranging from Delta through Omicron BA.5.2.

• Observational arm patients were treated with standard of care including monoclonal antibodies.

• Key observational findings: All treatment arm patients returned to their baseline level of health within 14 days of treatment. No evidence of COVID reinfection or Long COVID was observed in any treated patient at the time of the six (6) month follow up.

The stock traded up over 40% in the pre-market in reaction to the results.

The $0.35 area acted as support in the after-hours and pre-market and is an important level to watch.

Above it, targets to the upside are $0.40, $0.45 and then the pre-market high at $0.4870. Beyond that, $0.51, $0.57, $0.64 and $0.73 come into play.

Below $0.35, targets to the downside are $0.28 and then a gap fill at $0.2593.

TPST – Up over 40% in pre after announcing agreement with Roche to support advancement of Amezalpat combination therapy into first-line Hepatocellular Carcinoma pivotal trial

Tempest Therapeutics Inc. (TPST) is a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer.

In the pre-market the company announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.

Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. 

According to Finviz, based on yesterday’s close TPST had a market cap of just $34.03 million. Roce has a market cap of over $200 billion based on yesterday’s close according to Yahoo Finance.

TSPT stock traded up over 40% in the pre-market in reaction to the partnership.

The $1.74 area found buyers in the pre-market before breaking through resistance and will be an important level to watch.

Above it, targets to the upside are $1.88, $1.95 and then the pre-market high at $2.03. Beyond that, $2.20 and $2.70 come into play.

Below $1.74, targets to the downside are $1.60, $1.50, $1.40 and then a gap fill at $1.35.

MARKET NEWS 📰

P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!

Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull